Paul Peter Tak - 28 Nov 2022 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Chief Executive Officer, Director
Signature
/s/ Jason Amello, as Attorney-In-Fact for Paul Peter Tak
Issuer symbol
CADL
Transactions as of
28 Nov 2022
Net transactions value
$0
Form type
4
Filing time
30 Nov 2022, 17:30:52 UTC
Previous filing
01 Mar 2022
Next filing
12 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CADL Common Stock Award $0 +195,906 +784% $0.000000 220,906 28 Nov 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. 50% of the RSUs shall vest on November 28, 2023, and the remaining 50% on November 28, 2024, in each case subject to the Reporting Person's continued service on such vesting date.

Remarks:

Exhibit 24 - Power of Attorney